Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Oral Oncol. 2016 Aug;59:12–19. doi: 10.1016/j.oraloncology.2016.05.007

Fig. 2.

Fig. 2

Panel A Cell viability assay of HSC3 cells treated with Gefitinib (500 nM), TAE684 (500 nM), or both. Panel B: Cell viability assay of Cal27 cells treated with Gefitinib (500 nM), TAE684 (500 nM), or both. Panel C: Wound-healing assay of HSC3 cells treated with Gefitinib (500 nM), TAE684 (500 nM), or both. Panel D: Wound-healing assay of Cal27 cells treated with Gefitinib (500 nM), TAE684 (500 nM), or both. *p < 0.05, **p < 0.01, ***p < 0.001 treatment compared to control. #p < 0.05, ##p < 0.01, ###p < 0.001 Gefitinib compared to combination treatment. This data represents four replicates and error bars indicate SD.